Skip to content

Precision Risk Prediction and Efficacy Evaluation of Extracranial Vertebral Artery Stenosis Based on Computational Fluid Dynamics and Machine Learning

Precision Risk Prediction and Efficacy Evaluation of Extracranial Vertebral Artery Stenosis Based on Computational Fluid Dynamics and Machine Learning

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500112288
Enrollment
Unknown
Registered
2025-11-12
Start date
2025-11-15
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extracranial Vertebral Artery Stenosis, EVAS

Interventions

Best Medical Therapy Group (According to the Chinese Expert Consensus (2024) on Endovascular Treatment of Vertebral Artery Origin Stenosis, best medical therapy includes lipid management and antiplate
Drug-Eluting Stent Group (On the basis of best medical therapy, patients undergo implantation of a rapamycin-eluting (sirolimus-eluting) stent.):None

Sponsors

Xindu District People's Hospital of Chengdu
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1) Age >= 18 years; 2) Vertebral artery origin stenosis confirmed by CTA, MRA, or DSA, with a stenosis degree >= 50%; 3) The patient or legal representative has signed a written informed consent form and is willing to participate in follow-up.

Exclusion criteria

Exclusion criteria: 1) Non-atherosclerotic stenosis (e.g., arterial embolism, arterial dissection, moyamoya disease, vasculitis, etc.); 2) MRI showing new infarction or large territorial cerebral infarction; 3) Intracranial hemorrhage, brain tumor, or epidural/subdural hemorrhage; 4) Pre-onset modified Rankin Scale (mRS) score > 2; 5) Presence of aneurysm, vascular malformation, thrombus, or tandem stenosis at the target lesion site; 6) Vascular anatomical abnormalities or severe vessel tortuosity; 7) Myocardial infarction or major surgery within the past month; 8) Severe allergy to antiplatelet agents, anesthetics, or contrast media; 9) Recent gastrointestinal bleeding, active peptic ulcer, bleeding tendency, or coagulation disorders; 10) Uncontrolled severe hypertension; 11) Severe hepatic or renal dysfunction; 12) Dementia or psychiatric disorders that prevent cooperation or informed consent.

Design outcomes

Primary

MeasureTime frame
Incidence of stroke / transient ischemic attack ;intracranial hemodynamic parameters ;During model training/validation (after cross-validation and internal/external validation) and at follow-up endpoints for final validation.;

Countries

China

Contacts

Public ContactGuo Lei

Xindu District People's Hospital of Chengdu

grey.r74@foxmail.com+86 157 6055 1392

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026